WHO ICTRP trial
A combination of targeted radiation therapy (SBRT) and immunotherapy…
CTRI/2025/04/084493 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/04/084493 |
|---|---|
| Public title | A combination of targeted radiation therapy (SBRT) and immunotherapy (atezolizumab-bevacizumab) for treating liver cancer that cannot be removed by surgery. |
| Scientific title | Phase II, single arm prospective multicentre interventional study of SBRT (Stereotactic body radiotherapy) and Atezolizumab with Bevacizumab in unresectable Hepatocellular carcinoma |
| Primary sponsor | Tata Memorial Hospital |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: C220- Liver cell carcinoma |
| Interventions | Intervention1: Atezolizumab and Bevacizumab and SBRT: Patients enrolled in the study will receive a combination of Atezolizumab plus Bevacizumab and SBRT sequentially as follows 1. SBRT followed by Atezolizumab and Bevacizumab once every 3… |
| Registration date | Sep 4, 2025 |
| Target size | 62 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: